Colliers to Announce Second Quarter Results on August 2, 2023

TORONTO, July 12, 2023 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (TSX & NASDAQ: CIGI) (“Colliers” or the “Company”) today announced that results for the second quarter ended June 30, 2023 will be issued by press release on August 2, 2023 at approximately 7:00am ET.

A conference call to review these results will take place at 11:00am ET on August 2, 2023 and will be hosted by Jay S. Hennick, Chairman & CEO, Chris McLernon, CEO, Real Estate Services and Christian Mayer, CFO.

The telephone numbers for this call are: Local – Toronto 1-416-764-8658 and Toll Free – NA 1-888-886-7786 with conference ID 08567682. The conference call will also be accessible via webcast at https://corporate.colliers.com/events/default.aspx.

For anyone unable to listen to the scheduled call, the rebroadcast number will be 1-416-764-8692 or 1-877-674-7070 with passcode 567682#. The rebroadcast and archive recording of the conference call will be available at the above noted web address for 90 days following the call.

About ColliersColliers (NASDAQ, TSX: CIGI) is a leading diversified professional services and investment management company. With operations in 66 countries, our 18,000 enterprising professionals work collaboratively to provide expert real estate and investment advice to clients. For more than 28 years, our experienced leadership with significant inside ownership has delivered compound annual investment returns of approximately 20% for shareholders. With annual revenues of $4.5 billion and $98 billion of assets under management, Colliers maximizes the potential of property and real assets to accelerate the success of our clients, our investors, and our people. Learn more at corporate.colliers.com, Twitter @Colliers or LinkedIn.

Company Contact: Christian Mayer, CFOColliers International Group Inc.(416) 960-9500

Source: Colliers International Group Inc

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
• RedVeil Extends AI-Powered Penetration Testing Relief Package to Municipal Infrastructure Organizations
• Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress